Skip to main content

Table 2 Pregnancy and baby outcomes in relation to anti-malarial exposure status during first trimester

From: Safety of artemether-lumefantrine exposure in first trimester of pregnancy: an observational cohort

Pregnancy outcome

AL only

AL & Quinine

Quinine only

SP

Amodiaquine

None

 

164 (%)

8 (%)

70 (%)

66 (%)

11 (%)

1464 (%)

Abortion

5 (3.0)

2 (25.0)

3 (4.3)

0 (0.0)

0 (0.0)

34 (2.3)

Stillbirth

6 (3.7)

0 (0.0)

5 (7.1)

2 (3.0)

0 (0.0)

49 (3.3)

Live birth

153 (93.3)

6 (75.0)

62 (88.6)

64 (97.0)

11 (100)

1381 (94.3)

Birth maturity*

      

   Preterm birth

8 (5.2)

2 (33.3)

8 (12.9)

7 (10.9)

0 (0.0)

88 (6.4)

   Full term birth

145 (94.8)

4 (66.7)

54 (87.1)

57 (89.1)

11 (100)

1293 (93.6)

Birth weight*

      

   Low birth weight

8 (5.2)

1 (16.7)

1 (1.6)

2 (3.1)

0 (0.0)

69 (5.0)

   Normal birth weight

145 (94.8)

5 (83.3)

61 (98.4)

62 (96.9)

11 (100)

1312 (95.0)

Congenital anomalies

1 (0.6)

0 (0.0)

1 (1.4)

2 (3.0)

0 (0.0)

19 (1.3)

  1. Abbreviation: AL = Artemether-lumefantrine; SP = Sulphadoxine-pyrimethamine.
  2. *Excluded abortion and stillbirth outcomes.